Safety and Efficacy of Vaccination With Folate Receptor Alpha for Ovarian Cancer
04/01/2021
Roisin O'Cearbhaill, MD, Memorial Sloan Kettering Cancer Center, New York, discusses a phase 2 trial evaluating the safety and efficacy of TPIV200 versus GM-CSF alone in patients with high-grade, platinum-sensitive ovarian cancer, the data of which were presented at the virtual 2020 ASCO Annual Meeting.